This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XOMA Appoints Tom Klein To Newly Created Position Of Chief Commercial Officer

BERKELEY, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced Tom Klein has joined the Company as Chief Commercial Officer, a newly created position reporting to John Varian, XOMA's Chief Executive Officer. Mr. Klein brings over 25 years of successful brand commercialization leadership, with an expertise in commercializing biologic products to medical specialists. Mr. Klein joins XOMA from Genentech, where he was Vice President, Business Unit Head Virology and Specialty Care. 

"We created an executive-level position for commercial operations for two reasons. First, with the gevokizumab Phase 3 NIU program expected to begin delivering primary endpoint results at the end of this year and into the first half of next year, we are at the point where we are ready to begin building XOMA's launch strategy and commercialization plans. The importance of creating the sales and marketing plan for our first XOMA-developed product cannot be underestimated. We will build on Tom's vast experience to develop a launch program that maximizes the commercial potential of gevokizumab in the U.S. and that we can successfully execute from the day we hopefully receive BLA approval," stated Mr. Varian. "The second reason for creating a CCO position was to fully integrate market analyses into our clinical development decisions. The ability to foresee the commercial landscape of a clinical candidate early in the process is crucial to maximizing its commercial potential. Tom will draw on his years of experience and his vast network to provide our team with the most accurate information that will guide our second, third and fourth gevokizumab indications. The team and I are looking forward to working closely with Tom to ensure gevokizumab is a commercial success in the United States."

During his tenure with Genentech, Mr. Klein worked closely with both the Roche and Genentech teams to develop and execute commercial integration plans that met the needs of each company in their respective territories. Mr. Klein joined Genentech from Roche, where he had direct oversight over the Roche Hepatology and HIV Sales and Marketing teams and was responsible for ensuring affiliate and global strategic alignment. Prior to his 12 years with Roche, Mr. Klein spent 11 years with Westwood-Squibb/Bristol Myers-Squibb in a several sales and product management roles. Mr. Klein has launch experience in both the specialty and primary care markets, most recently with Boniva® (ibandronate sodium) for the treatment of osteoporosis in postmenopausal women. He also has been responsible for the category leading growth of Pegasys® (peginterferon alpha-2a) in HCV and market leadership of Pulmozyme® (dornase alfa) in cystic fibrosis, a rare disease area. Mr. Klein has a BA, Marketing, from Pennsylvania State University and an MBA, Management from Temple University.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs